256 related articles for article (PubMed ID: 24624866)
21. DNA methylation profiling of well-differentiated thyroid cancer uncovers markers of recurrence free survival.
Mancikova V; Buj R; Castelblanco E; Inglada-Pérez L; Diez A; de Cubas AA; Curras-Freixes M; Maravall FX; Mauricio D; Matias-Guiu X; Puig-Domingo M; Capel I; Bella MR; Lerma E; Castella E; Reverter JL; Peinado MÁ; Jorda M; Robledo M
Int J Cancer; 2014 Aug; 135(3):598-610. PubMed ID: 24382797
[TBL] [Abstract][Full Text] [Related]
22. Molecular predictors of local tumor control in early-stage breast cancer.
Miyamoto DT; Harris JR
Semin Radiat Oncol; 2011 Jan; 21(1):35-42. PubMed ID: 21134652
[TBL] [Abstract][Full Text] [Related]
23. Aging impacts transcriptomes but not genomes of hormone-dependent breast cancers.
Yau C; Fedele V; Roydasgupta R; Fridlyand J; Hubbard A; Gray JW; Chew K; Dairkee SH; Moore DH; Schittulli F; Tommasi S; Paradiso A; Albertson DG; Benz CC
Breast Cancer Res; 2007; 9(5):R59. PubMed ID: 17850661
[TBL] [Abstract][Full Text] [Related]
24. Companion diagnostic testing for targeted cancer therapies: an overview.
Fan YS
Genet Test Mol Biomarkers; 2013 Jul; 17(7):515-23. PubMed ID: 23574530
[TBL] [Abstract][Full Text] [Related]
25. [Contribution of molecular biology to new diagnostic and/or prognostic markers characterization in cancerogenesis].
de Fraipont F
Ann Biol Clin (Paris); 2007; 65(1):21-6. PubMed ID: 17264035
[TBL] [Abstract][Full Text] [Related]
26. Oncogenes and oncoproteins as tumor markers.
Pillai R
Eur J Surg Oncol; 1992 Oct; 18(5):417-24. PubMed ID: 1426290
[TBL] [Abstract][Full Text] [Related]
27. Analytical and clinical evaluation of a new urinary tumor marker: bladder tumor fibronectin in diagnosis and follow-up of bladder cancer.
Mutlu N; Turkeri L; Emerk K
Clin Chem Lab Med; 2003 Aug; 41(8):1069-74. PubMed ID: 12964816
[TBL] [Abstract][Full Text] [Related]
28. Multigene Panel Testing Detects Equal Rates of Pathogenic BRCA1/2 Mutations and has a Higher Diagnostic Yield Compared to Limited BRCA1/2 Analysis Alone in Patients at Risk for Hereditary Breast Cancer.
Kapoor NS; Curcio LD; Blakemore CA; Bremner AK; McFarland RE; West JG; Banks KC
Ann Surg Oncol; 2015 Oct; 22(10):3282-8. PubMed ID: 26219241
[TBL] [Abstract][Full Text] [Related]
29. Mixture classification model based on clinical markers for breast cancer prognosis.
Zeng T; Liu J
Artif Intell Med; 2010; 48(2-3):129-37. PubMed ID: 20005686
[TBL] [Abstract][Full Text] [Related]
30. Micromarkers 2.0: an update on the role of microRNAs in cancer diagnosis and prognosis.
Ferracin M; Negrini M
Expert Rev Mol Diagn; 2015; 15(10):1369-81. PubMed ID: 26338209
[TBL] [Abstract][Full Text] [Related]
31. [Alternative splicing regulation: implications in cancer diagnosis and treatment].
Martínez-Montiel N; Rosas-Murrieta N; Martínez-Contreras R
Med Clin (Barc); 2015 Apr; 144(7):317-23. PubMed ID: 24725854
[TBL] [Abstract][Full Text] [Related]
32. The Diagnostic and Prognostic Value of Tumor Markers (CEA, SCC, CYFRA 21-1, TPS) in Head and Neck Cancer Patients.
Barak V; Meirovitz A; Leibovici V; Rachmut J; Peretz T; Eliashar R; Gross M
Anticancer Res; 2015 Oct; 35(10):5519-24. PubMed ID: 26408719
[TBL] [Abstract][Full Text] [Related]
33. Integrated genetic and epigenetic analysis of bladder cancer reveals an additive diagnostic value of FGFR3 mutations and hypermethylation events.
Serizawa RR; Ralfkiaer U; Steven K; Lam GW; Schmiedel S; Schüz J; Hansen AB; Horn T; Guldberg P
Int J Cancer; 2011 Jul; 129(1):78-87. PubMed ID: 20824703
[TBL] [Abstract][Full Text] [Related]
34. Next generation sequencing technologies in cancer diagnostics and therapeutics: A mini review.
Li W; Zhao K; Kirberger M; Liao W; Yan Y
Cell Mol Biol (Noisy-le-grand); 2015 Oct; 61(5):91-102. PubMed ID: 26522064
[TBL] [Abstract][Full Text] [Related]
35. [A novel molecular marker for thrombus formation and life prognosis--clinical usefulness of measurement of soluble fibrin monomer-fibrinogen complex (SF)].
Koga S
Rinsho Byori; 2004 Apr; 52(4):355-61. PubMed ID: 15164605
[TBL] [Abstract][Full Text] [Related]
36. The emerging roles of DNA methylation in the clinical management of prostate cancer.
Perry AS; Foley R; Woodson K; Lawler M
Endocr Relat Cancer; 2006 Jun; 13(2):357-77. PubMed ID: 16728568
[TBL] [Abstract][Full Text] [Related]
37. Genome-wide methylation screen in low-grade breast cancer identifies novel epigenetically altered genes as potential biomarkers for tumor diagnosis.
Faryna M; Konermann C; Aulmann S; Bermejo JL; Brugger M; Diederichs S; Rom J; Weichenhan D; Claus R; Rehli M; Schirmacher P; Sinn HP; Plass C; Gerhauser C
FASEB J; 2012 Dec; 26(12):4937-50. PubMed ID: 22930747
[TBL] [Abstract][Full Text] [Related]
38. Prognostic and predictive markers in cancer.
Conley BA; Taube SE
Dis Markers; 2004; 20(2):35-43. PubMed ID: 15322312
[TBL] [Abstract][Full Text] [Related]
39. Biomarkers in molecular medicine: cancer detection and diagnosis.
Maruvada P; Wang W; Wagner PD; Srivastava S
Biotechniques; 2005 Apr; Suppl():9-15. PubMed ID: 16528918
[TBL] [Abstract][Full Text] [Related]
40. Overview of genetic diagnosis in cancer.
Korf B; M Mikhail F
Curr Protoc Hum Genet; 2007 Oct; Chapter 10():Unit 10.1. PubMed ID: 18428403
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
